CBP501, A novel anti-cancer drug candidate



MULTIMODAL MECHANISM OF ACTION

CBP501 is a novel calmodulin-modulating peptide with a well described multimodal anti-tumor mechanism of action




▲Go to page top

CLINICAL DATA

Clinical studies completed to evaluate the safety, and efficacy of CBP501




▲Go to page top

ONGOING CLINICAL TRIAL

Open-label multicenter Phase 1b study of combination therapy with CBP501, cisplatin and nivolumab for the treatment of advanced solid tumors




Study Results

- Of the 17 patients evaluable for response from dose escalation cohort, 3 heavily pretreated patients experienced a partial response (pancreatic, microsatellite stable colorectal and cholangiocarcinoma)
- 6 patients experienced tumor burden reduction (left)
- Disease control rate = 41% (defined as complete or partial response and >3 months stable disease)
- Patient with heavily pretreated pancreatic cancer with liver metastasis experienced a partial response and reduction in size of liver metastasis (right)
-Histology showed 70% PD-L1+ and 14% CD8+ cells
- Expansion cohorts for pancreatic cancer and microsatellite stable colorectal cancer are ongoing


▲Go to page top



CanBas' Focused Pipeline on Novel Cancer Targets




Visit our company website